Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck

Molecular Carcinogenesis

Volumn 50, Issue 9, 2011, Pages 697-706

  Yu, Hongping ^a   Huang, Yu Jing ^a   Liu, Zhensheng ^a   Wang, Li E ^a   Li, Guojun ^a   Sturgis, Erich M ^a   Johnson, David G ^a   Wei, Qingyi ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Age at onset; MDM2; p53; Polymorphism; Risk; Squamous cell carcinoma of the head and neck

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ALCOHOLISM; ARTICLE; CANCER RISK; CODON; FEMALE; GENETIC RISK; GENOME; GENOTYPE; HEAD AND NECK CARCINOMA; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CODON; DNA PRIMERS; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; YOUNG ADULT;

MURINAE;

EID: 79960621928     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20806     Document Type: Article

References (44)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
3. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622.
4. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20: 299-309.
5. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
6. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-953.
7. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25-27.
8. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 1999; 96: 3077-3080.
9. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998; 95: 15608-15612.
10. Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol 2005; 205: 206-220.
11. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: Cancer implications. Nat Rev Cancer 2009; 9: 95-107.
12. Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol 2010; 2: a001032.
13. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: A case-control study. Cancer Lett 2002; 183: 123-130.
14. Huang YJ, Niu J, Wei S, et al. A Novel functional DEC1 promoter polymorphism -249T>C reduces risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2010; 31: 2082-2090.
15. Guo Y, Jamison DC. The distribution of SNPs in human gene regulatory regions. BMC Genomics 2005; 6: 140.
16. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
17. Ries S, Biederer C, Woods D, et al. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF. Cell 2000; 103: 321-330.
18. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.
19. Post SM, Quintas-Cardama A, Pant V, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010; 18: 220-230.
20. Bouska A, Eischen CM. Mdm2 affects genome stability independent of p53. Cancer Res 2009; 69: 1697-1701.
21. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S. TP53 Arg72Pro polymorphism and colorectal cancer risk: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1840-1847.
22. Zhuo XL, Li Q, Zhou Y, et al. Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Arch Med Res 2009; 40: 625-634.
23. Fang F, Yu XJ, Yu L, Yao L. MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: A meta-analysis. Med Oncol 2010.
24. Sinilnikova OM, Antoniou AC, Simard J, et al. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2009; 101: 1456-1460.
25. Firoz EF, Warycha M, Zakrzewski J, et al. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res 2009; 15: 2573-2580.
26. Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 2009; 9: 13.
27. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 983-986.
28. Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog 2009; 48: 790-800.
29. Nakashima M, Kondo S, Shimizu Y, et al. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. Acta Otolaryngol 2008; 128: 808-813.
30. Huang SF, Chen IH, Liao CT, Wang HM, Liou SH, Hsieh LL. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol 2009; 45: 16-22.
31. Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol 2008; 87: 243-252.
32. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al. The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005; 42: 694-698.
33. Hamid S, Yang YH, Peng KN, et al. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. Oral Oncol 2009; 45: 496-500.
34. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
35. Applebaum KM, Furniss CS, Zeka A, et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007; 99: 1801-1810.
36. Gillespie MB, Rubinchik S, Hoel B, Sutkowski N. Human papillomavirus and oropharyngeal cancer: What you need to know in 2009. Curr Treat Options Oncol 2009; 10: 296-307.
37. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66: 5104-5110.
38. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 2006; 43: 950-952.
39. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15: 6529-6540.
40. Ishida H, Wada K, Masuda T, et al. Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma. Cancer Sci 2007; 98: 636-643.
41. Lukits J, Remenar E, Raso E, Ladanyi A, Kasler M, Timar J. Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer. Int J Oncol 2007; 30: 155-160.
42. Hu W, Feng Z, Ma L, et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007; 67: 2757-2765.
43. Kinyamu HK, Archer TK. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 2003; 23: 5867-5881.
44. Bartel F, Jung J, Bohnke A, et al. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 2008; 14: 89-96.